Table 1 Patient and B-CLL sample... | American Society of Hematology

Table 1

Patient and B-CLL sample characteristics

Patient	Location	Age, y	Rai stage	Lymph,* %	CD5⁺CD19⁺, %	CD19⁺, %	CD3⁺, %	IgV_H mutations†
B-CLL24	LN	52		> 90	ND	ND	ND	−
B-CLL27	LN	64	1	> 90	76	76	10	ND
B-CLL28	LN	80	4	> 90	64	93	8	−
B-CLL30	LN	46	3	> 90	37§	72	26	−
B-CLL33	LN	76	2	> 90	ND	ND	ND	−
B-CLL35	LN	67	2	> 90	ND	ND	ND	−
B-CLL36	LN	59	4	> 90	93	93	5	−
B-CLL37	PB	62	1	ND	ND	ND	ND	+
B-CLL38	PB	62	0	98	97	97	2	+
B-CLL39	PB	72	3	ND	94	98	3	+
B-CLL40	PB	70	3	93	48‡	98	1	−
B-CLL41	PB	ND	4	94	99	99	1	−
B-CLL42	PB	48	0	69	76	76	17	−
B-CLL43	PB	54	2	91	96	96	4	−
B-CLL44	PB	55	2	86	91	91	0	+
B-CLL45	PB	63	4	82	98	98	2	+
B-CLL46	PB	ND	ND	82	ND	ND	ND	ND
B-CLL47	PB	54	2	83	ND	ND	7	−
B-CLL48	PB	59	2	75	89	89	4	+
B-CLL50	PB	69	0	ND	99	99	3	+
B-CLL167‡	PB	70	0	62	84	86	11	+
B-CLL183‡	PB	78	0	47	94	95	4	+
B-CLL226‡	PB	64	1	70	98	98	1	−
B-CLL261‡	PB	77	4	32	92	92	4	+
B-CLL25	PB	68	2	ND	ND	78	13	−
B-CLL25	LN	68	2	> 90	82	83	20	−
B-CLL31	PB	72	2	ND	81	81	8	−
B-CLL31	LN	72	2	> 90	72	81	12	−

Patient	Location	Age, y	Rai stage	Lymph,* %	CD5⁺CD19⁺, %	CD19⁺, %	CD3⁺, %	IgV_H mutations†
B-CLL24	LN	52		> 90	ND	ND	ND	−
B-CLL27	LN	64	1	> 90	76	76	10	ND
B-CLL28	LN	80	4	> 90	64	93	8	−
B-CLL30	LN	46	3	> 90	37§	72	26	−
B-CLL33	LN	76	2	> 90	ND	ND	ND	−
B-CLL35	LN	67	2	> 90	ND	ND	ND	−
B-CLL36	LN	59	4	> 90	93	93	5	−
B-CLL37	PB	62	1	ND	ND	ND	ND	+
B-CLL38	PB	62	0	98	97	97	2	+
B-CLL39	PB	72	3	ND	94	98	3	+
B-CLL40	PB	70	3	93	48‡	98	1	−
B-CLL41	PB	ND	4	94	99	99	1	−
B-CLL42	PB	48	0	69	76	76	17	−
B-CLL43	PB	54	2	91	96	96	4	−
B-CLL44	PB	55	2	86	91	91	0	+
B-CLL45	PB	63	4	82	98	98	2	+
B-CLL46	PB	ND	ND	82	ND	ND	ND	ND
B-CLL47	PB	54	2	83	ND	ND	7	−
B-CLL48	PB	59	2	75	89	89	4	+
B-CLL50	PB	69	0	ND	99	99	3	+
B-CLL167‡	PB	70	0	62	84	86	11	+
B-CLL183‡	PB	78	0	47	94	95	4	+
B-CLL226‡	PB	64	1	70	98	98	1	−
B-CLL261‡	PB	77	4	32	92	92	4	+
B-CLL25	PB	68	2	ND	ND	78	13	−
B-CLL25	LN	68	2	> 90	82	83	20	−
B-CLL31	PB	72	2	ND	81	81	8	−
B-CLL31	LN	72	2	> 90	72	81	12	−

LN indicates lymph node; PB, peripheral blood; ND, not done.

Lymphocytes were investigated in the lymph node samples by immunohistochemistry and in the peripheral blood samples by FACS analysis.

IgV_H mutations were positive if ≥ 2% of the IgV_H gene was mutated.

These samples were used only for Western blot analyses.

These samples displayed low CD5 staining; therefore, the combined CD5/CD19 gate yielded low values.